Home Newsfeeds Keybanc Maintains Underweight on WestRock, Lowers Price Target to $36

Keybanc Maintains Underweight on WestRock, Lowers Price Target to $36

Keybanc analyst Adam Josephson maintains WestRock (NYSE:WRK) with a Underweight and lowers the price target from $44 to $36.

byBenzinga Newsdesk

July 1, 2022

1 minute read

Keybanc analyst Adam Josephson maintains WestRock (NYSE:WRK) with a Underweight and lowers the price target from $44 to $36.

Kohl’s Debt Overview

By Benzinga Insights

December 14, 3:21 PM

Over the past three months, shares of Kohl's Inc. (NYSE:KSS) decreased by 6.03%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.

KSS

FDA Has Granted Breakthrough Therapy Designation To Moderna’s Respiratory Syncytial Virus Vaccine Candidate, mRNA-1345

By Benzinga Newsdesk

January 30, 8:20 AM

The designation is based on topline data from the ConquerRSV Phase 3 efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease.The designation is based on topline data from the ConquerRSV Phase 3 efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease.

MRNA

News
SEC

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

By Benzinga Newsdesk

November 3, 2:01 AM

Ad Hoc Announcement Pursuant to Art.53 LR Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric

ADXN